Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06276036 · ClinicalTrials.gov registry record · NA
Autoimmune Cytopenias as a Sign of Primary Immunodeficiency.
A NA study of Cytopenia, sponsored by Meyer Children's Hospital IRCCS.
- Active
- Registry status
- NA
- Development phase
- 53
- Enrollment target
- 6
- Study locations
NCT06276036: Active NA study of Cytopenia, sponsored by Meyer Children's Hospital IRCCS.
NCT06276036 is a NA study of Cytopenia that is active but no longer recruiting, run by Meyer Children's Hospital IRCCS. The registered enrollment target is 53 participants, below the 374-participant average among 11 other Cytopenia trials with a reported enrollment target (86% lower). The trial reports 6 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06276036, a NA study of Cytopenia, is active but no longer recruiting, sponsored by Meyer Children's Hospital IRCCS.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 53 participants
- Enrollment target
- 6
- Study locations
Study Summary
Autoimmune cytopenias resistant to treatment are among the most common clinical manifestations observed in patients with congenital alterations of the immune system, such as primary immunodeficiencies (PI). The exact contribution of immune system alterations to the pathogenesis of autoimmune cytopenias has not yet been fully elucidated. Moreover, conventionally employed therapeutic strategies often fail, leading to increased healthcare costs, high morbidity, and even mortality. Therefore, there is a need to establish clinical guidelines for diagnosis and to identify early biomarkers capable of identifying individuals responsive to therapy. Thus, a systematic approach to the study of such pathologies will allow for the identification of early biomarkers and facilitate the development of targeted therapeutic strategies
Conditions Studied
Interventions
- OTHER Identification of specific markers
Study Locations (6)
Other
- Ghent University Hospital - Ghent
- Clinica Pediatrica - Università di Catania - Catania
- Meyer Children's Hospital IRCCS - Florence
- IRCCS Istituto Giannina Gaslini - Genova
- Azienda Ospedaliero Universitaria Pisana - Pisa
Florida
- University of South Florida - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2019-07-23 |
| Est. Completion | 2025-06-01 |
| Phase | NA |
What the registry record for NCT06276036 still lists
NCT06276036 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 374-participant average among 11 other Cytopenia trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Cytopenia appearing as the primary indexed condition, and to 1 intervention - of which Identification of specific markers is the first listed.
NCT06276036 lists 6 locations in 2 states (Other, Florida).
Frequently Asked Questions
What is clinical trial NCT06276036 about?
NCT06276036 is a clinical study titled "Autoimmune Cytopenias as a Sign of Primary Immunodeficiency.". Autoimmune cytopenias resistant to treatment are among the most common clinical manifestations observed in patients with congenital alterations of the immune system, such as primary immunodeficiencies (PI). The exact contribution of immune system alterations to the pathogenesis of autoimmune cytopen...
What is the current status of trial NCT06276036?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 53 participants. The study started on 2019-07-23. Estimated completion is 2025-06-01.
What conditions does trial NCT06276036 study?
This clinical trial studies the following conditions: Cytopenia.
What interventions are being tested in trial NCT06276036?
The interventions under investigation include: Identification of specific markers (OTHER).
Who is sponsoring clinical trial NCT06276036?
This trial is sponsored by Meyer Children's Hospital IRCCS, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06276036 being conducted?
This trial has 6 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cytopenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06276036's enrollment target sits among peer trials
53 7th of 11 higher than 5 of 11 other Cytopenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cytopenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
RECRUITING · NA
-
Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion
ACTIVE NOT RECRUITING · NA
-
Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies
ACTIVE NOT RECRUITING · NA
-
Development of a Peripheral Blood Assay to Replace BM Evaluation in Cytopenia - a Multi-Center Observational Study
RECRUITING
-
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
RECRUITING · Phase 2
-
Early Intervention in High Risk CCUS
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI